Literature DB >> 7721814

Direct involvement of the small GTP-binding protein Rho in lbc oncogene function.

Y Zheng1, M F Olson, A Hall, R A Cerione, D Toksoz.   

Abstract

The lbc oncogene is tumorigenic in nude mice, transforms NIH 3T3 fibroblasts, and encodes a Dbl homology domain found in several transforming gene products including the dbl oncogene product. While both lbc- and dbl-transformed NIH 3T3 foci exhibited a comparable gross appearance, lbc-transformed cell morphology was clearly distinct from that of dbl-transformed cells. Given these differences, we investigated the biochemical activity and target specificity of the Lbc oncoprotein both in vivo and in vitro. Here we show that Lbc associates specifically with the GTP-binding protein Rho in vivo, but not with the Ras, Rac, or Cdc42Hs GTP-binding proteins, and that recombinant, affinity-purified Lbc specifically catalyzes the guanine-nucleotide exchange activity of Rho in vitro. Consistent with an in vivo role for Lbc in Rho regulation, we further demonstrate that micro-injected onco-lbc potently induces actin stress fiber formation in quiescent Swiss 3T3 fibroblasts indistinguishable from that induced by Rho. Finally, lbc-induced NIH 3T3 focus formation is inhibited by co-transfection with a rho dominant-negative mutant. These results strongly indicate that the lbc oncogene encodes a specific guanine nucleotide exchange factor for Rho and causes cellular transformation through activation of the Rho signaling pathway.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7721814     DOI: 10.1074/jbc.270.16.9031

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

1.  Identification and characterization of a novel Rho-specific guanine nucleotide exchange factor.

Authors:  A Blomquist; G Schwörer; H Schablowski; A Psoma; M Lehnen; K H Jakobs; U Rümenapp
Journal:  Biochem J       Date:  2000-12-01       Impact factor: 3.857

2.  Induction of endogenous genes following infection of human endothelial cells with an E1(-) E4(+) adenovirus gene transfer vector.

Authors:  R Ramalingam; S Rafii; S Worgall; N R Hackett; R G Crystal
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

3.  The Guanine Nucleotide Exchange Factor Brx: A Link between Osmotic Stress, Inflammation and Organ Physiology and Pathophysiology.

Authors:  Tomoshige Kino; James H Segars; George P Chrousos
Journal:  Expert Rev Endocrinol Metab       Date:  2010-07-01

4.  Activation of the Lbc Rho exchange factor proto-oncogene by truncation of an extended C terminus that regulates transformation and targeting.

Authors:  P Sterpetti; A A Hack; M P Bashar; B Park; S D Cheng; J H Knoll; T Urano; L A Feig; D Toksoz
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

5.  The multidomain protein Trio binds the LAR transmembrane tyrosine phosphatase, contains a protein kinase domain, and has separate rac-specific and rho-specific guanine nucleotide exchange factor domains.

Authors:  A Debant; C Serra-Pagès; K Seipel; S O'Brien; M Tang; S H Park; M Streuli
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-28       Impact factor: 11.205

6.  Transformation by Rho exchange factor oncogenes is mediated by activation of an integrin-dependent pathway.

Authors:  M A Schwartz; D Toksoz; R Khosravi-Far
Journal:  EMBO J       Date:  1996-12-02       Impact factor: 11.598

7.  Cdc42 regulates anchorage-independent growth and is necessary for Ras transformation.

Authors:  R G Qiu; A Abo; F McCormick; M Symons
Journal:  Mol Cell Biol       Date:  1997-06       Impact factor: 4.272

8.  Autoinhibition mechanism of proto-Dbl.

Authors:  F Bi; B Debreceni; K Zhu; B Salani; A Eva; Y Zheng
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

9.  Rom1p and Rom2p are GDP/GTP exchange proteins (GEPs) for the Rho1p small GTP binding protein in Saccharomyces cerevisiae.

Authors:  K Ozaki; K Tanaka; H Imamura; T Hihara; T Kameyama; H Nonaka; H Hirano; Y Matsuura; Y Takai
Journal:  EMBO J       Date:  1996-05-01       Impact factor: 11.598

10.  Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia.

Authors:  Judith E Karp; Jeffrey E Lancet
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.